Lupin shares were in focus after a U.S. District Court rejected the proposal filed by generic firms (Zydus & Lupin) in a legal dispute with Astellas Pharma over the interpretation of the ‘189 patent. The case pertains to the key urology drug G Myrbetriq (mirabegron), used to treat overactive bladder.
The court’s decision is seen as a setback for generic challengers seeking to enter the market with versions of the drug ahead of patent expiry.
Lupin’s stock opened at ₹1,998.00, touched a high of ₹2,012.90 and a low of ₹1,980.00 during the session. The stock’s 52-week high stands at ₹2,402.90, while the 52-week low is ₹1,543.00. As of 9:51 AM, the shares were trading 0.59% lower at Rs 2,011.20.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash